OBJECTIVE: The authors examined whether D-cycloserine, a partial agonist at the glutamatergic N-methyl-d-aspartate receptor, augments and accelerates a full course of comprehensive cognitive-behavioral therapy (CBT) in adults with generalized social anxiety disorder. METHOD: This was a multisite randomized placebo-controlled efficacy study with 169 medication-free adults with generalized social anxiety disorder, of whom 144 completed the 12-week treatment and 131 completed the three follow-up assessments. Patients were randomly assigned to receive 50 mg of D-cycloserine or placebo 1 hour before each of five exposure sessions that were part of a 12-session cognitive-behavioral group treatment. Response and remission status was determined at baseline, throughout treatment, at end of treatment, and at 1-, 3-, and 6-month follow-up assessments by assessors who were blind to treatment condition. RESULTS:D-Cycloserine-augmented and placebo-augmented CBT were associated with similar completion rates (87% and 82%), response rates (79.3% and 73.3%), and remission rates (34.5% and 24.4%) at the posttreatment assessment; response and remission rates were largely maintained at the follow-up assessments. Although D-cycloserine was associated with a 24%-33% faster rate of improvement in symptom severity and remission rates relative to placebo during the treatment phase, the groups did not differ in response and remission rates. CONCLUSIONS:D-Cycloserine did not augment a full course of comprehensive CBT for social anxiety disorder.
RCT Entities:
OBJECTIVE: The authors examined whether D-cycloserine, a partial agonist at the glutamatergic N-methyl-d-aspartate receptor, augments and accelerates a full course of comprehensive cognitive-behavioral therapy (CBT) in adults with generalized social anxiety disorder. METHOD: This was a multisite randomized placebo-controlled efficacy study with 169 medication-free adults with generalized social anxiety disorder, of whom 144 completed the 12-week treatment and 131 completed the three follow-up assessments. Patients were randomly assigned to receive 50 mg of D-cycloserine or placebo 1 hour before each of five exposure sessions that were part of a 12-session cognitive-behavioral group treatment. Response and remission status was determined at baseline, throughout treatment, at end of treatment, and at 1-, 3-, and 6-month follow-up assessments by assessors who were blind to treatment condition. RESULTS:D-Cycloserine-augmented and placebo-augmented CBT were associated with similar completion rates (87% and 82%), response rates (79.3% and 73.3%), and remission rates (34.5% and 24.4%) at the posttreatment assessment; response and remission rates were largely maintained at the follow-up assessments. Although D-cycloserine was associated with a 24%-33% faster rate of improvement in symptom severity and remission rates relative to placebo during the treatment phase, the groups did not differ in response and remission rates. CONCLUSIONS:D-Cycloserine did not augment a full course of comprehensive CBT for social anxiety disorder.
Authors: R G Heimberg; M R Liebowitz; D A Hope; F R Schneier; C S Holt; L A Welkowitz; H R Juster; R Campeas; M A Bruch; M Cloitre; B Fallon; D F Klein Journal: Arch Gen Psychiatry Date: 1998-12
Authors: Adam J Guastella; Mark R Dadds; Peter F Lovibond; Philip Mitchell; Rick Richardson Journal: J Psychiatr Res Date: 2006-07-10 Impact factor: 4.791
Authors: M R Liebowitz; F Schneier; R Campeas; E Hollander; J Hatterer; A Fyer; J Gorman; L Papp; S Davies; R Gully Journal: Arch Gen Psychiatry Date: 1992-04
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Kerry J Ressler; Barbara O Rothbaum; Libby Tannenbaum; Page Anderson; Ken Graap; Elana Zimand; Larry Hodges; Michael Davis Journal: Arch Gen Psychiatry Date: 2004-11
Authors: Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto Journal: Arch Gen Psychiatry Date: 2006-03
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Jasper A J Smits; Michael J Zvolensky; Michael W Otto; Megan E Piper; Scarlett O Baird; Brooke Y Kauffman; Eunjung Lee-Furman; Noura Alavi; Christina D Dutcher; Santiago Papini; Benjamin Rosenfield; David Rosenfield Journal: Drug Alcohol Depend Date: 2020-01-22 Impact factor: 4.492
Authors: Alicia E Meuret; Michael Chmielewski; Ashton M Steele; David Rosenfield; Sibylle Petersen; Jasper A J Smits; Naomi M Simon; Michael W Otto; Luana Marques; Mark H Pollack; Stefan G Hofmann Journal: Behav Res Ther Date: 2016-04-02
Authors: Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin Journal: Neurobiol Learn Mem Date: 2013-12-07 Impact factor: 2.877
Authors: Eric A Storch; Sabine Wilhelm; Susan Sprich; Aude Henin; Jamie Micco; Brent J Small; Joseph McGuire; P Jane Mutch; Adam B Lewin; Tanya K Murphy; Daniel A Geller Journal: JAMA Psychiatry Date: 2016-08-01 Impact factor: 21.596